KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Accumulated Expenses (2016 - 2026)

Bio-Rad Laboratories has reported Accumulated Expenses over the past 18 years, most recently at $148.4 million for Q1 2026.

  • Quarterly Accumulated Expenses fell 5.72% to $148.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $148.4 million through Mar 2026, down 5.72% year-over-year, with the annual reading at $172.3 million for FY2025, 38.73% up from the prior year.
  • Accumulated Expenses was $148.4 million for Q1 2026 at Bio-Rad Laboratories, down from $172.3 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $194.8 million in Q4 2022 and troughed at $124.2 million in Q4 2024.
  • The 5-year median for Accumulated Expenses is $157.4 million (2025), against an average of $161.4 million.
  • Year-over-year, Accumulated Expenses decreased 29.68% in 2022 and then soared 38.73% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $194.8 million in 2022, then decreased by 28.18% to $139.9 million in 2023, then dropped by 11.22% to $124.2 million in 2024, then skyrocketed by 38.73% to $172.3 million in 2025, then dropped by 13.87% to $148.4 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Accumulated Expenses are $148.4 million (Q1 2026), $172.3 million (Q4 2025), and $182.8 million (Q3 2025).